Active surveillance: The Canadian experience

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 222-230

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

active surveillance; conservative management; favorable risk prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL TRIAL (TOPIC); FOLLOW UP; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

AGED; BIOPSY; CANADA; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; PATIENT SELECTION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84859645406     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328352598c     Document Type: Review

References (19)

1. Cooperberg MR, Broering JM, Carroll PR. Time trends in treatment of localized prostate cancer. J Clin Oncol 2010; 28:1117-1123. This study of treatment trends in management of localized prostate cancer in the USA, based on the CaPSURE database, emphasizes that overtreatment of low-grade prostate cancer continues to the present day.
2. Matzkin H, Patel JP, Altwein JE, Soloway MS. Stage T1A carcinoma of prostate. Urology 1994; 43:11-21. (Pubitemid 2017122)
3. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167:1664-1669. (Pubitemid 34240696)
4. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23:8165-8169. (Pubitemid 46211550)
5. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006; 176 (4 Pt 1):1392-1397.
6. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010; 184:131-135.
7. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126-131. This article is the most recent publication describing the Toronto cohort managed with active surveillance. This is the most mature and one of the largest cohorts in the active surveillance literature.
8. Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174 (4 Pt 1):1256-1260. (Pubitemid 41318696)
9. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178:2359-2364.
10. Soloway MS, Soloway CT, Williams S, et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008; 101:165-169. (Pubitemid 350294039)
11. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51:1244-1250.
12. Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007; 120:170-174.
13. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010; 105:956-962.
14. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54:1297-1305.
15. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience, J Urol 1994; 152:1753.
16. Johansson JE, Andrén O, Andersson S, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291:2713-271916.
17. Klotz L. Thompson I Early prostate cancer: treat or watch? N Engl J Med 2011; 365:569. This letter is a response to the third publication of the Scandinavian randomized trial of radical prostatectomy vs. watchful waiting, which showed a trend to an improved survival in 'low-risk' prostate cancer patients treated with surgery. The letter points out that the mortality in the radical prostatectomy arm of the trial is much higher than in the Toronto active surveillance cohort, suggesting that the 'low-risk' patients in the Scandinavian trial, which was carried out in an unscreened population, were not in fact low risk by contemporary standards.
18. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302:1202-1209.
19. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433-439. (Pubitemid 41124175)